Toward the Design of Allosteric Effectors: Gaining Comprehensive Control of Drug Properties and Actions
Journal of Medicinal Chemistry · 10.10.2024 · 67 (19) · 17191-17206
DOI: 10.1021/acs.jmedchem.4c01043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 26.09.2024. Verfasst von Wei-Ven Tee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), 30 Biopolis Street, #07-01, Matrix, Singapore 138671, Singapore. Hauptthemen laut MEDLINE: Drug Design, Allosteric Site. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agency for Science, Technology and Research, Ministry of Health -Singapore.
Abstract (Originalsprache)
While the therapeutic potential of allosteric drugs is increasingly realized, the discovery of effectors is largely incidental. The rational design of allosteric effectors requires new state-of-the-art approaches to account for the distinct characteristics of allosteric ligands and their modes of action. We present a broadly applicable computational framework for obtaining allosteric site-effector pairs, providing targeted, highly specific, and tunable regulation to any functional site. We validated the framework using the main protease from SARS-CoV-2 and the K-RasG12D oncoprotein. High-throughput per-residue quantification of the energetics of allosteric signaling and effector binding revealed known drugs capable of inducing the required modulation upon binding. Starting from fragments of known well-characterized drugs, allosteric effectors and binding sites were designed and optimized simultaneously to achieve targeted and specific signaling to distinct functional sites, such as, for example, the switch regions of K-RasG12D. The generic framework proposed in this work will be instrumental in developing allosteric therapies aligned with a precision medicine approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), 30 Biopolis Street, #07-01, Matrix, Singapore 138671, Singapore.
- Department of Biological Sciences (DBS), National University of Singapore (NUS), 8 Medical Drive, Singapore 117579, Singapore.
ORCID-Profile: Igor N Berezovsky
Förderung
- Agency for Science, Technology and Research
- Ministry of Health -Singapore
Zitieren
APA
Tee, W. V., Lim, S. J. M., & Berezovsky, I. N. (2024). Toward the Design of Allosteric Effectors: Gaining Comprehensive Control of Drug Properties and Actions. Journal of Medicinal Chemistry, 67(19), 17191-17206. https://doi.org/10.1021/acs.jmedchem.4c01043
Vancouver
Tee WV, Lim SJM, Berezovsky IN. Toward the Design of Allosteric Effectors: Gaining Comprehensive Control of Drug Properties and Actions. Journal of Medicinal Chemistry. 2024;67(19):17191-17206. doi:10.1021/acs.jmedchem.4c01043
BibTeX
@article{Tee2024,
author = {Tee, Wei-Ven and Lim, Sylvester J M and Berezovsky, Igor N},
title = {Toward the Design of Allosteric Effectors: Gaining Comprehensive Control of Drug Properties and Actions},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {19},
pages = {17191--17206},
doi = {10.1021/acs.jmedchem.4c01043}
}
EUVIMED